Merck & Co., Inc. and Eisai announce Phase 3 trial results for WELIREG plus LENVIMA in advanced… EP News Bureau Oct 29, 2025 LITESPARK-011 trial meets primary endpoint of progression-free survival in patients previously treated with anti-PD-1/L1 therapy
